David J Venzon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6697508/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 545-551.	1.8	624
2	Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome. Journal of Clinical Oncology, 1999, 17, 615-615.	0.8	353
3	Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood, 2001, 98, 979-987.	0.6	279
4	Vaccine-Elicited Antibodies Mediate Antibody-Dependent Cellular Cytotoxicity Correlated with Significantly Reduced Acute Viremia in Rhesus Macaques Challenged with SIVmac251. Journal of Immunology, 2005, 174, 2185-2189.	0.4	278
5	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479.	0.2	229
6	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770.	15.2	197
7	A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. Journal of Immunological Methods, 2006, 308, 53-67.	0.6	192
8	Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. Journal of Clinical Investigation, 2019, 129, 2357-2373.	3.9	176
9	Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nature Medicine, 2000, 6, 1140-1146.	15.2	174
10	Protection against Mucosal Simian Immunodeficiency Virus SIV mac251 Challenge by Using Replicating Adenovirus-SIV Multigene Vaccine Priming and Subunit Boosting. Journal of Virology, 2004, 78, 2212-2221.	1.5	173
11	Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. Journal of Urology, 1995, 154, 2010-2015.	0.2	170
12	Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20738-20743.	3.3	136
13	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. Journal of Virology, 2013, 87, 1708-1719.	1.5	130
14	Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIV _{mac251} Challenge of Rhesus Macaques. Journal of Virology, 2009, 83, 791-801.	1.5	125
15	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	2.0	97
16	Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies. Journal of Virology, 2005, 79, 10200-10209.	1.5	95
17	Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Recombinant Priming and Envelope Protein Boosting Elicits Localized, Mucosal IgA Immunity in Rhesus Macaques Correlated with Delayed Acquisition following a Repeated Low-Dose Rectal SIV _{mac251} Challenge. Journal of Virology, 2012, 86, 4644-4657.	1.5	95
18	DNA Vaccines Expressing Different Forms of Simian Immunodeficiency Virus Antigens Decrease Viremia upon SIVmac251 Challenge. Journal of Virology, 2005, 79, 8480-8492.	1.5	93

#	Article	IF	CITATIONS
19	PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. Journal of Urology, 2000, 163, 431-433.	0.2	91
20	Resection of primary tumor site isÂassociated with prolonged survival inÂmetastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery, 2016, 159, 311-319.	1.0	91
21	Potentiation of Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cell Responses by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen. Journal of Immunology, 2001, 167, 7180-7191.	0.4	89
22	Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9843-9848.	3.3	88
23	A PHASE 2 STUDY OF RADIO FREQUENCY INTERSTITIAL TISSUE ABLATION OF LOCALIZED RENAL TUMORS. Journal of Urology, 2000, 163, 1424-1427.	0.2	87
24	A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV 89.6P Challenge in Rhesus Macaques. Journal of Virology, 2007, 81, 3414-3427.	1.5	80
25	Vaccine-Induced CD8+Central Memory T Cells in Protection from Simian AIDS. Journal of Immunology, 2005, 175, 3502-3507.	0.4	79
26	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	3.6	77
27	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.4	76
28	Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nature Medicine, 2001, 7, 1225-1231.	15.2	73
29	A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1669-1678.	2.5	72
30	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2975-2980.	3.3	71
31	Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncolmmunology, 2017, 6, e1308616.	2.1	71
32	Metastatic melanoma: Correlation of MRI characteristics and histopathology. Journal of Magnetic Resonance Imaging, 1996, 6, 190-194.	1.9	70
33	Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. , 1999, 85, 1470-1483.		68
34	Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4 + T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIV KU2 RNA Levels. Journal of Virology, 2006, 80, 3732-3742.	1.5	67
35	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nature Medicine, 2018, 24, 847-856.	15.2	65
36	Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: Role of SIV-specific CD8+ T cell responses. Virology, 2006, 353, 83-98.	1.1	64

#	Article	IF	CITATIONS
37	Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes. PLoS Pathogens, 2018, 14, e1006902.	2.1	62
38	An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 270-277.	0.9	61
39	DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15831-15836.	3.3	61
40	Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. PLoS Pathogens, 2015, 11, e1005101.	2.1	59
41	Vaccine-induced myeloid cell population dampens protective immunity to SIV. Journal of Clinical Investigation, 2014, 124, 2538-2549.	3.9	58
42	Taxol in combination with doxorubicin or etoposide possible antagonism in vitro. Cancer, 1993, 72, 2705-2711.	2.0	57
43	Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry Part B - Clinical Cytometry, 2011, 80B, 83-90.	0.7	57
44	Reduced Protection from Simian Immunodeficiency Virus SIV _{mac251} Infection Afforded by Memory CD8 ⁺ T Cells Induced by Vaccination during CD4 ⁺ T-Cell Deficiency. Journal of Virology, 2008, 82, 9629-9638.	1.5	54
45	Dynamics of Memory B-Cell Populations in Blood, Lymph Nodes, and Bone Marrow during Antiretroviral Therapy and Envelope Boosting in Simian Immunodeficiency Virus SIVmac251-Infected Rhesus Macaques. Journal of Virology, 2012, 86, 12591-12604.	1.5	54
46	Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemotherapy and Pharmacology, 1997, 40, 117-125.	1.1	53
47	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV _{mac251} at Challenge Exposure. Journal of Virology, 2013, 87, 3538-3548.	1.5	52
48	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight, 2021, 6, .	2.3	52
49	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology, 2021, 80, 746-757.	0.9	50
50	Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine, 2011, 29, 3310-3319.	1.7	49
51	Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. Journal of Virology, 2016, 90, 2195-2207.	1.5	46
52	Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route. Vaccine Journal, 2012, 19, 629-637.	3.2	44
53	4′â€modified nucleoside analogs: Potent inhibitors active against entecavirâ€resistant hepatitis B virus. Hepatology, 2015, 62, 1024-1036.	3.6	43
54	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. Cell Reports, 2020, 31, 107624.	2.9	43

#	Article	IF	CITATIONS
55	DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques. PLoS ONE, 2014, 9, e91550.	1.1	42
56	TRIM5α Does Not Affect Simian Immunodeficiency Virus SIV _{mac251} Replication in Vaccinated or Unvaccinated Indian Rhesus Macaques following Intrarectal Challenge Exposure. Journal of Virology, 2011, 85, 12399-12409.	1.5	40
57	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	1.5	39
58	Co-dependence of HTLV-1 p12 and p8 Functions in Virus Persistence. PLoS Pathogens, 2014, 10, e1004454.	2.1	36
59	Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 230-241.	2.0	35
60	Sampling Strategies for Analysis of Enterochromaffin-like Cell Changes in Zollinger-Ellison Syndrome. American Journal of Clinical Pathology, 2000, 114, 419-425.	0.4	34
61	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. Journal of Immunology, 2014, 193, 6172-6183.	0.4	34
62	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. Journal of Immunology, 2016, 197, 2726-2737.	0.4	34
63	Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaques. Mucosal Immunology, 2018, 11, 1219-1229.	2.7	33
64	Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leukemia Research, 2018, 71, 106-111.	0.4	33
65	Assessment of Tumor Growth in Pancreatic Neuroendocrine Tumors in von Hippel Lindau Syndrome. Journal of the American College of Surgeons, 2014, 218, 163-169.	0.2	32
66	Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. Clinical Immunology, 2014, 153, 264-276.	1.4	32
67	Sequential Priming with Simian Immunodeficiency Virus (SIV) DNA Vaccines, with or without Encoded Cytokines, and a Replicating Adenovirus-SIV Recombinant Followed by Protein Boosting Does Not Control a Pathogenic SIV _{mac251} Mucosal Challenge. Journal of Virology, 2008, 82, 10911-10921.	1.5	31
68	Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120. Journal of Immunology, 2015, 195, 3227-3236.	0.4	31
69	A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer, 1993, 72, 663-668.	2.0	30
70	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. Frontiers in Immunology, 2021, 12, 658428.	2.2	30
71	Prognostic Value of Initial Fasting Serum Gastrin Levels in Patients With Zollinger-Ellison Syndrome. Journal of Clinical Oncology, 2001, 19, 3051-3057.	0.8	28
72	B Cell Responses Associated with Vaccine-Induced Delayed SIVmac251 Acquisition in Female Rhesus Macaques. Journal of Immunology, 2016, 197, 2316-2324.	0.4	28

#	Article	IF	CITATIONS
73	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. Journal of Clinical Investigation, 2019, 129, 1314-1328.	3.9	28
74	Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-AâZO1 negative rhesus macaques. Virology, 2008, 374, 322-337.	1.1	27
75	Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Journal of Virology, 2018, 92, .	1.5	26
76	Mucosal-associated invariant T (MAIT) cells provide B-cell help in vaccinated and subsequently SIV-infected Rhesus Macaques. Scientific Reports, 2020, 10, 10060.	1.6	26
77	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793953.	2.2	25
78	Mucosal and Systemic Î ³ δ+ T Cells Associated with Control of Simian Immunodeficiency Virus Infection. Journal of Immunology, 2016, 197, 4686-4695.	0.4	24
79	Mesothelin-targeted immunotoxin RC7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget, 2017, 8, 9189-9199.	0.8	24
80	Five-Year Follow-Up of a Phase I Study of Didanosine in Patients with Advanced Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1995, 171, 1180-1189.	1.9	23
81	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology, 2014, 471-473, 81-92.	1.1	21
82	Neutrophil Vaccination Dynamics and Their Capacity To Mediate B Cell Help in Rhesus Macaques. Journal of Immunology, 2018, 201, 2287-2302.	0.4	21
83	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clinical Immunology, 2014, 153, 308-322.	1.4	20
84	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. Oncologist, 2017, 22, 505-e49.	1.9	20
85	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 275-282.	0.7	20
86	Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. Journal of Hepatology, 2021, 74, 1075-1086.	1.8	20
87	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. PLoS Pathogens, 2019, 15, e1008121.	2.1	19
88	Early T Follicular Helper Cell Responses and Germinal Center Reactions Are Associated with Viremia Control in Immunized Rhesus Macaques. Journal of Virology, 2019, 93, .	1.5	19
89	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer, 2016, 101, 104-110.	0.9	18
90	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. Thyroid, 2019, 29, 79-92.	2.4	18

6

#	Article	IF	CITATIONS
91	Effects of tumor necrosis factor, alone or in combination with topoisomerase-ii-targeted drugs, on human lung cancer cell lines. International Journal of Cancer, 1990, 46, 326-329.	2.3	17
92	CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	17
93	Associations of Simian Immunodeficiency Virus (SIV)-Specific Follicular CD8+ T Cells with Other Follicular T Cells Suggest Complex Contributions to SIV Viremia Control. Journal of Immunology, 2018, 200, 2714-2726.	0.4	16
94	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	1.9	16
95	Loss of marginal zone B-cells in SHIVSF162P4 challenged rhesus macaques despite control of viremia to low or undetectable levels in chronic infection. Virology, 2015, 484, 323-333.	1.1	15
96	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 137, 896-907.	0.6	15
97	Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindau–Associated Pancreatic Lesions. Journal of the American College of Surgeons, 2014, 218, 997-1003.	0.2	14
98	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathogens, 2020, 16, e1008377.	2.1	14
99	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro-Oncology, 2022, 24, 1978-1988.	0.6	14
100	Rhesus macaque rectal and duodenal tissues exhibit B-cell sub-populations distinct from peripheral blood that continuously secrete antigen-specific IgA in short-term explant cultures. Vaccine, 2014, 32, 872-880.	1.7	12
101	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. PLoS Pathogens, 2021, 17, e1009701.	2.1	12
102	Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2022, 13, 796349.	2.2	12
103	Enhanced In Vitro Transcytosis of Simian Immunodeficiency Virus Mediated by Vaccine-Induced Antibody Predicts Transmitted/Founder Strain Number After Rectal Challenge. Journal of Infectious Diseases, 2015, 211, 45-52.	1.9	11
104	Effects of the Deletion of Early Region 4 (E4) Open Reading Frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on Virus-Host Cell Interaction, Transgene Expression, and Immunogenicity of Replicating Adenovirus HIV Vaccine Vectors. PLoS ONE, 2013, 8, e76344.	1.1	11
105	NK cells and monocytes modulate primary HTLV-1 infection. PLoS Pathogens, 2022, 18, e1010416.	2.1	11
106	Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine, 2011, 29, 6017-6028.	1.7	10
107	Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology, 2013, 440, 210-221.	1.1	10
108	Differential Effect of Mucosal NKp44+Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques. Journal of Immunology, 2019, 203, 2459-2471.	0.4	10

#	Article	IF	CITATIONS
109	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
110	Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy. Annals of Surgical Oncology, 1996, 3, 198-203.	0.7	9
111	Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer Prevention Research, 2016, 9, 225-233.	0.7	8
112	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. Journal of Virology, 2020, 94, .	1.5	8
113	Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. , 2022, 10, e004601.		8
114	Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. Journal of Virology, 2016, 90, 8487-8495.	1.5	7
115	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	7
116	7-Deaza-7-fluoro modification confers on 4′-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. Antiviral Research, 2020, 176, 104744.	1.9	7
117	Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. PLoS ONE, 2016, 11, e0158505.	1.1	7
118	A Pathogenic Role for Splenic B1 Cells in SIV Disease Progression in Rhesus Macaques. Frontiers in Immunology, 2019, 10, 511.	2.2	6
119	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. International Journal of Molecular Sciences, 2020, 21, 896.	1.8	6
120	Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d. Frontiers in Immunology, 2019, 10, 2355.	2.2	5
121	Evaluation of the Relative Cytotoxic Effects of Anticancer Agents in Serum-supplemented versus Serum-free Media Using a Tetrazolium Colorimetric Assay. Japanese Journal of Cancer Research, 1996, 87, 91-97.	1.7	4
122	Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIV _{mac251} Acquisition. AIDS Research and Human Retroviruses, 2014, 30, A64-A65.	0.5	3
123	Influence of Plasma Cell Niche Factors on the Recruitment and Maintenance of IRF4 ^{hi} Plasma Cells and Plasmablasts in Vaccinated, Simian Immunodeficiency Virus-Infected Rhesus Macaques with Low and High Viremia. Journal of Virology, 2017, 91, .	1.5	3
124	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemotherapy and Pharmacology, 2017, 80, 217-221.	1.1	3
125	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports, 2019, 9, 14884.	1.6	3
126	Iterative epigenomic analyses in the same single cell. Genome Research, 2021, 31, 1819-1830.	2.4	3

#	Article	IF	CITATIONS
127	Nitric oxide modulation enhances the in vivo protection from lethal irradiation by stem cell factor. Radiation Oncology Investigations, 1994, 2, 264-268.	1.3	2
128	Suramin administration is associated with a decrease in serum calcium levels. World Journal of Urology, 2000, 18, 388-391.	1.2	2
129	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. AIDS Research and Human Retroviruses, 2014, 30, A99-A99.	0.5	2
130	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leukemia and Lymphoma, 2018, 59, 178-186.	0.6	2
131	Impact on the fitness of N95 masks with extended use/limited reuse and dry heat decontamination. Journal of Investigative Medicine, 2021, , jim-2021-001908.	0.7	2
132	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma Journal of Clinical Oncology, 2013, 31, 10588-10588.	0.8	2
133	Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib Journal of Clinical Oncology, 2017, 35, 10540-10540.	0.8	2
134	Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Current Oncology, 2021, 28, 4357-4366.	0.9	2
135	E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. Vaccines, 2022, 10, 295.	2.1	2
136	Phenylacetate Pharmacokinetics Based on Iterative Two-Stage Population Analysis. Pharmacotherapy, 2001, 21, 281-286.	1.2	1
137	The Immunological Impact of Adenovirus Early Genes on Vaccine-Induced Responses in Mice and Nonhuman Primates. Journal of Virology, 2021, 95, .	1.5	1
138	A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. , 1993, 72, 663.		1
139	DNA and Protein Co-immunization Improves the Magnitude, Longevity, and Mucosal Dissemination of Immune Responses. AIDS Research and Human Retroviruses, 2014, 30, A63-A64.	0.5	0
140	Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2919-2928.	1.8	0
141	Reusable Single Cell for Iterative Epigenomic Analyses. Journal of Visualized Experiments, 2022, , .	0.2	0